Genetic variation in the DNA repair pathway as a potential determinant of response to platinum‐based chemotherapy in breast cancer

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of Cellular Physiology

• Publication date

  2018-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jcp.26091PMID 28696006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 134 A novel role for keratin 17 during the DNA damage response and cancer

  2019cited by this paper
• The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs

  2018cited by this paper
• Role of Wnt/β‐catenin signaling regulatory microRNAs in the pathogenesis of colorectal cancer

  2018cited by this paper
• Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress

  2018cited by this paper
• The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress

  2018cited by this paper
• Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin‐based chemotherapy

  2018cited by this paper
• A genetic variant in CDKN2A/B gene is associated with the increased risk of breast cancer

  2018cited by this paper
• The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress

  2018cited by this paper
• Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways

  2018cited by this paper
• Role of adenosine signaling in the pathogenesis of breast cancer

  2018cited by this paper
• ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy

  2017cited by this paper
• Therapeutic Potentials of BDNF/TrkB in Breast Cancer; Current Status and Perspectives

  2017cited by this paper
• Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives

  2017cited by this paper
• Current Status and Perspectives Regarding the Therapeutic Potential of Targeting EGFR Pathway by Curcumin in Lung Cancer.

  2017cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• DNA repair targeted therapy: The past or future of cancer treatment?

  2016cited by this paper
• Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer.

  2015cited by this paper
• Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

  2015influential reference
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

  2015cited by this paper
• Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

  2015cited by this paper
• Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

  2014cited by this paper
• BRCA1 Pathway Function in Basal-Like Breast Cancer Cells

  2014cited by this paper
• Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.

  2014cited by this paper
• ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients

  2013cited by this paper
• Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.

  2013cited by this paper
• Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.

  2013cited by this paper
• The DNA damage response and cancer therapy

  2012cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer

  2011cited by this paper
• Prescott's Microbiology.

  2011influential reference
• Global cancer statistics

  2011cited by this paper
• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  2011cited by this paper
• Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients.

  2011cited by this paper
• Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers

  2011cited by this paper
• Trends in cancer mortality in Brazil, 1980–2004

  2010cited by this paper
• Management of breast cancer in Nepal.

  2009cited by this paper
• Eukaryotic Translesion Polymerases and Their Roles and Regulation in DNA Damage Tolerance

  2009cited by this paper
• CORRELATION OF XPD/ERCC2 POLYMORPHISM WITH CLINICAL SENSITIVITY TO OXALIPLATIN-BASED CHEMOTHERAPY IN ADVANCED COLORECTAL CANCER

  2009cited by this paper
• Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

  2009cited by this paper
• The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.

  2008cited by this paper
• DNA repair pathways as targets for cancer therapy

  2008cited by this paper
• Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity

  2008cited by this paper
• Mechanisms of resistance to cisplatin and carboplatin.

  2007cited by this paper
• Fanconi anemia and DNA replication repair.

  2007cited by this paper
• The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks

  2007cited by this paper
• Molecular mechanisms of resistance and toxicity associated with platinating agents.

  2007cited by this paper
• Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.

  2006cited by this paper
• Purification and characterization of Escherichia coli and human nucleotide excision repair enzyme systems.

  2006cited by this paper
• Translesion synthesis in mammalian cells.

  2006cited by this paper
• DNA helicases required for homologous recombination and repair of damaged replication forks.

  2006cited by this paper
• Breast Cancer in Limited‐Resource Countries: An Overview of the Breast Health Global Initiative 2005 Guidelines

  2006cited by this paper
• Chemotherapy and the war on cancer

  2005cited by this paper
• ERCC1 and Clinical Resistance to Platinum-Based Therapy

  2005cited by this paper
• Cancer cell adaptation to chemotherapy

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Cellular processing of platinum anticancer drugs

  2005cited by this paper
• ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Distinct roles of DNA polymerases delta and epsilon at the replication fork in Xenopus egg extracts

  2004cited by this paper
• Cancer Disparities by Race/Ethnicity and Socioeconomic Status

  2004cited by this paper
• The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair.

  2004cited by this paper
• Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.

  2004cited by this paper
• Breast cancer and hormone-replacement therapy in the Million Women Study.

  2003cited by this paper
• Breast cancer and hormone-replacement therapy: the Million Women Study.

  2003cited by this paper
• The Bloom's syndrome helicase suppresses crossing over during homologous recombination

  2003cited by this paper
• Polymorphisms in the DNA repair gene XRCC1 and breast cancer.

  2001cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Gene-expression profiles in hereditary breast cancer.

  2001cited by this paper
• Human Mus81-associated endonuclease cleaves Holliday junctions in vitro.

  2001cited by this paper
• Mechanisms of accurate translesion synthesis by human DNA polymerase η

  2000cited by this paper
• The Bloom's syndrome gene product promotes branch migration of holliday junctions.

  2000cited by this paper
• Strategies for cloning mammalian DNA repair genes.

  1999cited by this paper
• The Werner Syndrome Gene Product Co-purifies with the DNA Replication Complex and Interacts with PCNA and Topoisomerase I*

  1999cited by this paper
• Quality of life in the first year after breast cancer surgery: rehabilitation needs and patterns of recovery

  1999cited by this paper
• Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer.

  1997cited by this paper
• Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents.

  1994cited by this paper
• Mismatch repair, genetic stability, and cancer.

  1994cited by this paper
• A model for tumor response to chemotherapy: an integration of the stem cell and somatic mutation hypotheses.

  1985cited by this paper
• The importance of dose intensity in chemotherapy of metastatic breast cancer.

  1984cited by this paper
• [Trends in cancer mortality].

  1983cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• Platinum Compounds: a New Class of Potent Antitumour Agents

  1969cited by this paper
• Molecular Biology of the Gene

  1965cited by this paper

• Genetic Polymorphisms in Base Excision Repair (BER) and Nucleotide Excision Repair (NER) Pathways as Potential Biomarkers for Gynecological Cancers: A Comprehensive Literature Review

  2025cites this paper
• Cardiotoxicity in platinum-based chemotherapy: Mechanisms, manifestations, and management

  2024cites this paper
• Machine learning for genetic prediction of chemotherapy toxicity in cervical cancer.

  2023cites this paper
• Human Serum Albumin-Oxaliplatin (Pt(IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer.

  2023cites this paper
• IMAGGS: a radiogenomic framework for identifying multi-way associations in breast cancer subtypes.

  2023cites this paper
• Excision Repair Cross-Complementation Group 6 Gene Polymorphism Is Associated with the Response to FOLFIRINOX Chemotherapy in Asian Patients with Pancreatic Cancer

  2021cites this paper
• Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy

  2021cites this paper
• Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance.

  2021cites this paper
• ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers

  2020cites this paper
• The multi-factorial nature of clinical multidrug resistance in cancer.

  2019cites this paper
• Current status and future prospects of transforming growth factor‐β as a potential prognostic and therapeutic target in the treatment of breast cancer

  2019cites this paper
• Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer

  2019cites this paper
• Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer

  2018cites this paper
• Therapeutic potency of oncolytic virotherapy in breast cancer targeting, current status and perspective

  2018cites this paper
• association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis

  2018cites this paper
• Association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis

  2018cites this paper